Log in to your Inderes Free account to see all free content on this page.
Medivir
2.16 SEK
-4.43 %
Less than 1K followers
MVIR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Medivir
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 8.7 | 13.9 | 25.5 | 4.4 | 7.6 | 3.5 | 8.5 |
| growth-% | 59.8 % | 83.5 % | -82.7 % | 72.7 % | -53.9 % | 142.9 % | |
| EBITDA | -118.9 | -38.5 | -59.5 | -84.8 | -88.7 | -124.6 | -60.1 |
| EBIT | -126.0 | -42.9 | -62.1 | -87.4 | -91.4 | -127.3 | -92.6 |
| Profit before taxes | -123.3 | -42.6 | -62.6 | -88.8 | -89.3 | -123.3 | -94.4 |
| Net income | -123.4 | -42.6 | -63.1 | -88.8 | -89.3 | -123.3 | -94.4 |
| EPS | -3.42 | -1.18 | -0.98 | -1.30 | -1.48 | -1.08 | -0.66 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -1,366.7 % | -277.0 % | -233.3 % | -1,927.3 % | -1,167.1 % | -3,560.0 % | -707.1 % |
| EBIT-% | -1,448.3 % | -308.6 % | -243.5 % | -1,986.4 % | -1,202.6 % | -3,637.1 % | -1,089.4 % |
| ROE | -66.9 % | -30.0 % | -22.4 % | -46.1 % | -41.0 % | -106.8 % | -35.7 % |
| ROI | -42.0 % | -22.2 % | -18.8 % | -37.9 % | -31.0 % | -71.4 % | -30.8 % |
Login required
This content is only available for logged in users